Statistically, 70% of cancer patients show hormone-receptor-positive/ERBB2-negative phenotype, while 15% to 20% are ERBB2-positive and another 15% have triple-negative tumors (TNBC) missing all three standard molecular markers. Here, ERBB2 is linked to cancer.